Ulcerative Colitis And Crohns Flashcards
Fill the table.
Management of CD: Inducing remission and Maintenance for
(a) Mild-to-moderate CD
(b) Moderate-to-severe CD
(c) Fistulating disease.
Use the statement that best fits the explanation for the statements below:
(a) Cost-effectiveness
(b) efficacy
(c) acceptability
(d) Safety
1. Azathioprine used instead of inflixamab
2. Azathoprine used instead of methotrexate.
3. Inflixmab used in isolation instead of adding DMARD
4.Budesonide selected over prednisolone.
- (a) Cost-effectiveness
- (d) Both agents have same therapeutic efficacy but azathioprine has a faster onset. Safety is the main concern with methotrexate. It is high risk drug.
- (b) Efficacious, significantly higher rates of corticosteroid-free clinical remission and mucosal healing at week 26 among patients with active Crohn’s disease who did not have a response to first-line therapy.
- (d) Budesonide has less systemic activity than prednisolone.
Management of UC: Inducing remission and Maintenance for
(a) Mild UC
(b) Moderate UC
(c) Severe UC
Which treatment has a fast/slow onset.
What are the co-morbidities associated with treatment of UC and CD.
MAO Azathioprine and 6-MP
Onset of Azathioprine/6-MP
Therapeutic effect of Aza/6-MP
What drug increases the levels Aza/6-MP.
(A) Allopurinol
(B) Amlodipine
(C) Carbamazepine
(D) Inflixamab
Side effects of AZA/6-MP
Monitoring for AZA and 6-MP
MAO of 5-ASA and what is the benefit of using 5-ASA is UC.